MoFo Life Sciences

Contact
Share
Info
Firm Profile: Morrison & Foerster LLP
425 Market Street
San Francisco, CA 94105-2482, United States
Phone: (415) 268-7000
Fax: (415) 268-7522
Areas Of Practice
  • Health
Locations
Other U.S. Locations
  • California
  • Colorado
  • D.C.
  • New York
  • Virginia
Other Countries
  • Belgium
  • China
  • Germany
  • Hong Kong
  • Japan
  • Singapore
  • United Kingdom

Establishing Unexpected Results: PTAB Highlights Pitfalls For Rule 132 Declarations

A recent decision by the Patent Trial and Appeal Board (PTAB) sheds light on certain pitfalls patent applicants may encounter when submitting declarations under 37 C.F.R. § 1.132 (“Rule 132 Declarations”). Rule 132 Declarations…more
 /  Intellectual Property

Beyond Final Rejection: What’s Next For Patent Prosecution After USPTO Terminates Its After Final Consideration Program?

On October 1, 2024, the United States Patent and Trademark Office (USPTO) announced that it is terminating its After Final Consideration Pilot Program 2.0 (AFCP 2.0), which is set to expire on December 14, 2024. The expiration…more
 /  Intellectual Property

Under Lock And Key – Private Sales May Not Qualify As Public Disclosure

Recently, the Federal Circuit affirmed a PTAB decision finding that a private sale of a product did not constitute a public disclosure by the inventor of the product. The Leahy-Smith America Invents Act provides exceptions for…more
 /  Intellectual Property

Federal Circuit Clarifies Scope Of Obviousness-Type Double Patenting In Allergan USA V. MSN Laboratories

On August 13, 2024, the U.S. Court of Appeals for the Federal Circuit issued a welcomed decision to patentees in Allergan USA, Inc. v. MSN Laboratories Private Ltd., No. 24-1061 (Fed. Cir. 2024) clarifying the scope of…more
 /  Business Organizations, Intellectual Property, Science, Computers, & Technology

Senate Unanimously Passes Bill To Limit Patent Infringement Challenges By Drug Manufacturers

The Affordable Prescriptions for Patients Act (APPA) of 2023 unanimously passed the Senate on July 11, 2024. The APPA was first introduced to the House on January 30, 2023 by Representative John Cornyn (R-Tx), with the aim of…more
 /  Health, Intellectual Property, Science, Computers, & Technology

The PTAB Axes Skin Treatment Patent Under Amgen

The Patent Trial and Appeal Board (“PTAB”) recently invalidated a University of Massachusetts (“UMass”) patent related to the treatment of the skin disease vitiligo in a post-grant review. (See Forte Biosciences Inc v…more
 /  Health, Intellectual Property, Science, Computers, & Technology

Microbes, Biotech Investigations, And Impacts: Midsummer Regulatory Updates From USDA-APHIS

After overhauling its biotechnology regulations for plants developed using genetic engineering, the United States Department of Agriculture’s Animal and Plant Health Inspection Service (USDA-APHIS) is again reevaluating its…more
 /  Administrative Law, Agriculture, Health, Science, Computers, & Technology

USPTO Seeks Input On Experimental Use Exception To Patent Infringement And Possible Legislative Action

On June 28, 2024, the United States Patent and Trademark Office (USPTO) issued a Notice requesting public comments on the current state of the common law experimental use exception to patent infringement and whether Congress…more
 /  Intellectual Property, Science, Computers, & Technology

Federal Court Invalidates Dosing Patent Based On Clinical Trials Disclosure

As an essential component of the drug development process, human clinical trials assist in determining whether a given drug will serve its intended purpose, but patent applicants should consider disclosure of such trials in…more
 /  Health, Intellectual Property, Science, Computers, & Technology

USPTO Considers Changing Terminal Disclaimer Practice To Require Agreement Regarding Enforceability

On May 10, 2024, the USPTO issued a Notice of Proposed Rulemaking that proposes major changes to terminal disclaimer practice that could greatly affect both patent prosecution and patent litigation strategies. Specifically, the…more
 /  Intellectual Property

Non-Lab Diagnostics: FDA Regulatory Considerations

The advent of the COVID-19 rapid antigen test launched at-home diagnostics to the forefront of conversation in the life sciences industry. Many believe this is only the beginning. As the share of telehealth services increases,…more
 /  Science, Computers, & Technology

USPTO Issues Reminder To Examiners On Proper “Means-Plus-Function” Analysis

On March 18, 2024, the USPTO issued a memorandum to its Examiners reminding them of the resources and proper analysis for interpreting limitations under 35 U.S.C. § 112(f), which are commonly referred to as “means-plus-function”…more
 /  Intellectual Property, Science, Computers, & Technology

At-Home Diagnostics Articles: Non-Lab Diagnostics: Supply, Manufacturing, And Distribution Agreements

The advent of the COVID-19 rapid antigen test launched at-home diagnostics to the forefront of conversation in the life sciences industry. Many believe this is only the beginning. As the share of telehealth services increases,…more
 /  Health, Intellectual Property, Science, Computers, & Technology

Non-Lab Diagnostics: Consumer And User Agreements

The advent of the COVID-19 rapid antigen test launched at-home diagnostics to the forefront of conversation in the life sciences industry. Many believe this is only the beginning. As the share of telehealth services increases,…more
 /  Consumer Protection, Health, Intellectual Property, Privacy, Science, Computers, & Technology

UPOV Updates Explanatory Note On Essentially Derived Varieties (EDVS)

In October 2023, the International Union for the Protection of New Varieties of Plants (UPOV) published a long-awaited updated Explanatory Note on Essentially Derived Varieties (EDVs). The UPOV Convention outlines a popular sui…more
 /  Intellectual Property, Science, Computers, & Technology
Showing 1-15 of 155 Results
/
View per page
Page: of 11
This profile may constitute attorney advertising. Prior results do not guarantee a similar outcome. Any correspondence with this profile holder does not constitute a client/attorney relationship. Neither the content on this profile nor transmissions between you and the profile holder through this profile are intended to provide legal or other advice or to create an attorney-client relationship.

"My best business intelligence,
in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide